SCHEDULE: ABVC Biopharma Chairman Consolidates Significant Voting Power
Beneficial Ownership Report
ABVC Biopharma's Chairman and Chief Business Officer, Eugene Jiang, has significantly increased his voting control over the company's common stock, now holding 18.50% of outstanding shares through direct ownership and various voting agreements.
Summary
- Eugene Jiang, Chairman and Chief Business Officer of ABVC Biopharma, Inc., now has voting control over 3,102,265 shares of the Issuer's Common Stock.
- This represents 18.50% of the outstanding and issued Common Stock of ABVC Biopharma, Inc., based on 16,773,261 shares outstanding as of June 27, 2025.
- Jiang's voting control is derived from 131,159 shares held directly, sole voting power over 829,699 shares held by YuanGene Corporation, and sole voting power over an aggregate of 2,141,407 shares held by others, including 153,850 'Summer Shares'.
- The 'Summer Shares' were issued between June 20, 2025, and July 1, 2025, to Non-U.S. Persons under Regulation S, generating aggregate gross proceeds of $200,000 for the company.
- Investors who acquired the 'Summer Shares' entered into Voting Rights Proxy Agreements, transferring all their voting rights to Eugene Jiang for the maximum time permitted by law.
Sentiment
Score: 5
Explanation: The document is a factual report on beneficial ownership and voting control, not a performance or strategic update, thus maintaining a neutral sentiment.
Positives
- The company received $200,000 in gross proceeds from the sale of 153,850 shares to investors.
Management Comments
- Certain of the Issuer's shareholders sought to grant the Reporting Person voting rights with respect to such shareholder's shares.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Voting Rights Consolidation | Shareholders, including YuanGene Corporation and investors in the 'Summer Shares,' entered into Voting Rights Proxy Agreements to transfer sole voting rights over their shares to Eugene Jiang. | Between June 20, 2025 and July 1, 2025 (for Summer Shares) | Consolidates significant voting power (18.50%) under the Chairman and Chief Business Officer, potentially strengthening management's control over corporate decisions and strategic direction. |
Related Party Transactions
- Voting Rights Proxy Agreements were entered into by investors of the 'Summer Shares' to transfer voting rights to Eugene Jiang.
- Eugene Jiang was appointed as the person with sole voting power over shares held by YuanGene Corporation.
Stakeholder Impact
- Shareholders: Significant consolidation of voting power under one executive, potentially impacting the influence of other shareholders in corporate governance and decision-making.
- Management: Strengthened control and influence over company direction and strategic decisions due to increased voting power held by the Chairman and Chief Business Officer.
Key Dates
| Date | Description |
|---|---|
| June 20, 2025 | Start date for the period during which 'Summer Shares' were issued. |
| June 27, 2025 | Date as of which 16,773,261 shares of Common Stock were issued and outstanding. |
| July 1, 2025 | End date for the period during which 'Summer Shares' were issued. |
| July 10, 2025 | Date of the event which required the filing of this statement. |
| July 15, 2025 | Date of signature for the Schedule 13D filing. |
Keywords
ABVC Biopharma, Eugene Jiang, Beneficial Ownership, Voting Control, Common Stock, SEC Filing, Corporate Governance, Schedule 13D
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.